Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01684397 · ClinicalTrials.gov registry record · Phase 1

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

A Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by Roswell Park Cancer Institute.

Active
Registry status
Phase 1
Development phase
51
Enrollment target
5
Study locations

NCT01684397 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 51 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01684397, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
51 participants
Enrollment target
5
Study locations

Study Summary

This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Bevacizumab
  • OTHER Pharmacological Study
  • DRUG Pazopanib Hydrochloride

Study Locations (5)

Kansas

  • The University of Kansas Cancer Center - Westwood

Michigan

  • Karamanos Cancer Institute - Detroit

New York

  • Roswell Park Cancer Institute - Buffalo

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2012-11-21
Est. Completion 2026-08-20
Phase Phase 1

Sponsor

Roswell Park Cancer Institute

365 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01684397

The ClinicalTrials.gov registry entry for NCT01684397 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01684397 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Kansas, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT01684397 about?

NCT01684397 is a clinical study titled "Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer". This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of ...

What is the current status of trial NCT01684397?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2012-11-21. Estimated completion is 2026-08-20.

What conditions does trial NCT01684397 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer.

What interventions are being tested in trial NCT01684397?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER), Pazopanib Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01684397?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01684397 being conducted?

This trial has 5 study locations across Kansas, Michigan, New York, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Stage IV Renal Cell Cancer

All registered trials for this condition

Kansas

All trials with a study site in Kansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.